Porphyromonas gingivalis impairs glucose uptake in skeletal muscle associated with altering gut microbiota.
Adipose Tissue
/ metabolism
Adult
Aged
Animals
Antibodies, Bacterial
/ blood
Bacteroidaceae Infections
/ metabolism
Blood Glucose
/ metabolism
Cell Line, Transformed
Diet, High-Fat
Feces
/ microbiology
Female
Gastrointestinal Microbiome
/ genetics
Glucose Intolerance
/ metabolism
Humans
Immunoglobulin G
/ blood
Insulin Resistance
Japan
/ epidemiology
Male
Metabolic Syndrome
/ blood
Mice
Mice, Inbred C57BL
Middle Aged
Muscle, Skeletal
/ metabolism
Myoblasts
/ metabolism
Periodontal Diseases
/ blood
Porphyromonas gingivalis
/ genetics
RNA, Ribosomal, 16S
/ genetics
Porphyromonas gingivalis
glucose uptake
metabolic syndrome
periodontal disease
skeletal muscle
Journal
FASEB journal : official publication of the Federation of American Societies for Experimental Biology
ISSN: 1530-6860
Titre abrégé: FASEB J
Pays: United States
ID NLM: 8804484
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
received:
11
05
2020
revised:
30
09
2020
accepted:
26
10
2020
pubmed:
17
11
2020
medline:
29
6
2021
entrez:
16
11
2020
Statut:
ppublish
Résumé
Skeletal muscles have a high metabolic capacity, which play key roles in glucose metabolism. Although periodontal disease increases the risk of metabolic syndrome, the relationship between periodontal bacterial infection and skeletal muscle metabolic dysfunction is unclear. We found that anti-Porphyromonas gingivalis (Pg) antibody titers positively correlated with intramuscular adipose tissue content (IMAC), fasting blood glucose, and HOMA-IR in metabolic syndrome patients. In C57BL/6J mice fed a high-fat diet, recipients of oral Pg (HFPg) had impaired glucose tolerance, insulin resistance, and higher IMAC compared to recipients of saline (HFco). The soleus muscle in HFPg mice exhibited fat infiltration and lower glucose uptake with higher Tnfa expression and lower insulin signaling than in HFco mice. Gene set enrichment analysis showed that TNFα signaling via NFκB gene set was enriched in the soleus muscle of HFPg mice. Moreover, TNF-α also decreased glucose uptake in C2C12 myoblast cells in vitro. Based on 16S rRNA sequencing, Pg administration altered the gut microbiome, particularly by decreasing the abundance of genus Turicibacter. Microbial network of the gut microbiome was dramatically changed by Pg administration. Our findings suggest that infection with Pg is a risk factor for metabolic syndrome and skeletal muscle metabolic dysfunction via gut microbiome alteration.
Identifiants
pubmed: 33197074
doi: 10.1096/fj.202001158R
doi:
Substances chimiques
Antibodies, Bacterial
0
Blood Glucose
0
Immunoglobulin G
0
RNA, Ribosomal, 16S
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e21171Informations de copyright
© 2020 Federation of American Societies for Experimental Biology.
Références
Frontera WR, Ochala J. Skeletal muscle: a brief review of structure and function. Calcif Tissue Int. 2015;96:183-195.
Shadrin IY, Khodabukus A, Bursac N. Striated muscle function, regeneration, and repair. Cell Mol Life Sci. 2016;73:4175-4202.
Giudice J, Taylor JM. Muscle as a paracrine and endocrine organ. Curr Opin Pharmacol. 2017;34:49-55.
Meyer C, Dostou JM, Welle SL, Gerich JE. Role of human liver, kidney, and skeletal muscle in postprandial glucose homeostasis. Am J Physiol Endocrinol Metab. 2002;282:E419-E427.
Zimmet P, Magliano D, Matsuzawa Y, Alberti G, Shaw J. The metabolic syndrome: a global public health problem and a new definition. J Atheroscler Thromb. 2005;12:295-300.
McCracken E, Monaghan M, Sreenivasan S. Pathophysiology of the metabolic syndrome. Clin Dermatol. 2018;36:14-20.
Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:2735-2752.
Pihlstrom BL, Michalowicz BS, Johnson NW. Periodontal diseases. Lancet. 2005;366:1809-1820.
Amano A, Nakagawa I, Okahashi N, Hamada N. Variations of Porphyromonas gingivalis fimbriae in relation to microbial pathogenesis. J Periodontal Res. 2004;39:136-142.
Saito T, Shimazaki Y, Sakamoto M. Obesity and periodontitis. N Engl J Med. 1998;339:482-483.
Martinez-Herrera M, Silvestre-Rangil J, Silvestre FJ. Association between obesity and periodontal disease. A systematic review of epidemiological studies and controlled clinical trials. Med Oral Patol Oral Cir Bucal. 2017;22:e708-e715.
Preshaw PM, Alba AL, Herrera D, et al. Periodontitis and diabetes: a two-way relationship. Diabetologia. 2012;55:21-31.
Lamster IB, Pagan M. Periodontal disease and the metabolic syndrome. Int Dent J. 2017;67:67-77.
Komazaki R, Katagiri S, Takahashi H, et al. Periodontal pathogenic bacteria, Aggregatibacter actinomycetemcomitans affect non-alcoholic fatty liver disease by altering gut microbiota and glucose metabolism. Sci Rep. 2017;7:13950.
Teramoto T, Sasaki J, Ueshima H, et al. Metabolic syndrome. J Atheroscler Thromb. 2008;15:1-5.
Kitajima Y, Takahashi H, Akiyama T, et al. Supplementation with branched-chain amino acids ameliorates hypoalbuminemia, prevents sarcopenia, and reduces fat accumulation in the skeletal muscles of patients with liver cirrhosis. J Gastroenterol. 2018;53:427-437.
Udagawa S, Katagiri S, Maekawa S, et al. Effect of Porphyromonas gingivalis infection in the placenta and umbilical cord in pregnant mice with low birth weight. Acta Odontol Scand. 2018;76:433-441.
Sasaki N, Katagiri S, Komazaki R, et al. Endotoxemia by Porphyromonas gingivalis injection aggravates non-alcoholic fatty liver disease, disrupts glucose/lipid metabolism, and alters gut microbiota in Mice. Front Microbiol. 2018;9:2470.
Katagiri S, Park K, Maeda Y, et al. Overexpressing IRS1 in endothelial cells enhances angioblast differentiation and wound healing in diabetes and insulin resistance. Diabetes. 2016;65:2760-2771.
Toyoda T, An D, Witczak CA, et al. Myo1c regulates glucose uptake in mouse skeletal muscle. J Biol Chem. 2011;286:4133-4140.
Bolyen E, Rideout JR, Dillon MR, et al. Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2. Nat Biotechnol. 2019;37:852-857.
Mandal S, Van Treuren W, White RA, Eggesbø M, Knight R, Peddada SD. Analysis of composition of microbiomes: a novel method for studying microbial composition. Microb Ecol Health Dis. 2015;26:27663.
Friedman J, Alm EJ. Inferring correlation networks from genomic survey data. PLoS Comput Biol. 2012;8:e1002687.
Shiba T, Watanabe T, Kachi H, et al. Distinct interacting core taxa in co-occurrence networks enable discrimination of polymicrobial oral diseases with similar symptoms. Sci Rep. 2016;6:30997.
Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102:15545-15550.
Pajak B, Siwiak E, Sołtyka M, et al. 2-Deoxy-d-glucose and its analogs: from diagnostic to therapeutic agents. Int J Mol Sci. 2019;21:234.
Eke PI, Dye BA, Wei L, et al. Update on prevalence of periodontitis in adults in the United States: NHANES 2009 to 2012. J Periodontol. 2015;86:611-622.
Kim OS, Shin MH, Kweon SS, et al. The severity of periodontitis and metabolic syndrome in Korean population: The Dong-gu study. J Periodontal Res. 2018;53:362-368.
Hajishengallis G, Liang S, Payne MA, et al. Low-abundance biofilm species orchestrates inflammatory periodontal disease through the commensal microbiota and complement. Cell Host Microbe. 2011;10:497-506.
Mysak J, Podzimek S, Sommerova P, et al. Porphyromonas gingivalis: major periodontopathic pathogen overview. J Immunol Res. 2014;2014:476068.
Kojima T, Yano K, Ishikawa I. Relationship between serum antibody levels and subgingival colonization of Porphyromonas gingivalis in patients with various types of periodontitis. J Periodontol. 1997;68:618-625.
Kudo C, Naruishi K, Maeda H, et al. Assessment of the plasma/serum IgG test to screen for periodontitis. J Dent Res. 2012;91:1190-1195.
Jensen J, Rustad PI, Kolnes AJ, Lai Y-C. The role of skeletal muscle glycogen breakdown for regulation of insulin sensitivity by exercise. Front Physiol. 2011;2:112.
Schiaffino S, Reggiani C. Fiber types in mammalian skeletal muscles. Physiol Rev. 2011;91:1447-1531.
Kammoun M, Cassar-Malek I, Meunier B, Picard B. A simplified immunohistochemical classification of skeletal muscle fibres in mouse. Eur J Histochem. 2014;58:2254.
Hua N, Takahashi H, Yee GM, et al. Influence of muscle fiber type composition on early fat accumulation under high-fat diet challenge. PLoS ONE. 2017;12:e0182430.
Zimowska M, Kasprzycka P, Bocian K, et al. Inflammatory response during slow- and fast-twitch muscle regeneration. Muscle Nerve. 2017;55:400-409.
Dean DJ, Brozinick JT, Cushman SW, Cartee GD. Calorie restriction increases cell surface GLUT-4 in insulin-stimulated skeletal muscle. Am J Physiol. 1998;275:E957-E964.
King GL, Park K, Li Q. selective insulin resistance and the development of cardiovascular diseases in diabetes: The 2015 Edwin Bierman Award Lecture. Diabetes. 2016;65:1462-1471.
Baker RG, Hayden MS, Ghosh S. NF-κB, inflammation, and metabolic disease. Cell Metab. 2011;13:11-22.
Iwata M, Haruta T, Usui I, et al. Pioglitazone ameliorates tumor necrosis factor-alpha-induced insulin resistance by a mechanism independent of adipogenic activity of peroxisome proliferator-activated receptor-gamma. Diabetes. 2001;50:1083-1092.
Nishimura F, Iwamoto Y, Mineshiba J, Shimizu A, Soga Y, Murayama Y. Periodontal disease and diabetes mellitus: the role of tumor necrosis factor-α in a 2-way relationship. J Periodontol. 2003;74:97-102.
Sun W-L, Chen L-L, Zhang S-Z, Wu Y-M, Ren Y-Z, Qin G-M. Inflammatory cytokines, adiponectin, insulin resistance and metabolic control after periodontal intervention in patients with type 2 diabetes and chronic periodontitis. Intern Med. 2011;50:1569-1574.
Page RC. The pathobiology of periodontal diseases may affect systemic diseases: inversion of a paradigm. Ann Periodontol. 1998;3:108-120.
Li Y, Luan Y, Yue X, et al. Effects of Codonopis bulleynana forest ex diels on Deferribacteres in constipation predominant intestine tumor: Differential analysis. Saudi J Biol Sci. 2019;26:395-401.
Fernández-Real JM, McClain D, Manco M. Mechanisms linking glucose homeostasis and iron metabolism toward the onset and progression of type 2 diabetes. Diabetes Care. 2015;38:2169.
Zhu L, Baker SS, Gill C, et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology. 2013;57:601-609.
Zhong Y, Nyman M, Fåk F. Modulation of gut microbiota in rats fed high-fat diets by processing whole-grain barley to barley malt. Mol Nutr Food Res. 2015;59:2066-2076.
Vrieze A, Van Nood E, Holleman F, et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology. 2012;143:913-916.e917.
Lahiri S, Kim H, Garcia-Perez I, et al. The gut microbiota influences skeletal muscle mass and function in mice. Sci Transl Med. 2019;11:eaan5662.
Raza GS, Putaala H, Hibberd AA, et al. Polydextrose changes the gut microbiome and attenuates fasting triglyceride and cholesterol levels in Western diet fed mice. Sci Rep. 2017;7:5294.
Everard A, Lazarevic V, Gaïa N, et al. Microbiome of prebiotic-treated mice reveals novel targets involved in host response during obesity. ISME J. 2014;8:2116-2130.
Rosenberg IH. Sarcopenia: origins and clinical relevance. J Nutr. 1997;127:990S-991S.
Zoico E, Di Francesco V, Guralnik JM, et al. Physical disability and muscular strength in relation to obesity and different body composition indexes in a sample of healthy elderly women. Int J Obes Relat Metab Disord. 2004;28:234-241.
Batsis JA, Villareal DT. Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies. Nat Rev Endocrinol. 2018;14:513-537.
Janssen I, Heymsfield SB, Ross R. Low relative skeletal muscle mass (sarcopenia) in older persons is associated with functional impairment and physical disability. J Am Geriatr Soc. 2002;50:889-896.
Janssen I, Shepard DS, Katzmarzyk PT, Roubenoff R. The healthcare costs of sarcopenia in the United States. J Am Geriatr Soc. 2004;52:80-85.